[Congress] Bio Europe, October 26-29, 2020

[Congress] Bio Europe, October 26-29, 2020

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.

This is time to choose your scientific partner, that is why we propose you to discover our integrated drug discovery & development solution.

An integrated drug discovery & development solution from hit finding to IND filing in less than 3 years

DRIVE™ is part of Oncodesign’s continuous commitment to improve its integrated drug discovery offer DRIVE™.
This joint offering encompasses all drug discovery skills, expertise and platforms to deliver drugs in major therapeutic areas including oncology, immuno-oncology, immuno-inflammation and inflammation.
DRIVE™ runs a multiparametric optimization mode, with streamlined and fast testing of newly synthesized compounds. By applying immediate processing, within a collaborative environment between medicinal chemists, in vitro/in vivo pharmacologists and DMPK specialists, Oncodesign helps reduce the iterative cycles of optimization to rapidly deliver preclinical candidates.

DRIVE™ premium solution timeline

DRIVE™ premium solution timeline

Our expert Emily Fang will participate to give you the answers you need to make the right decisions at the right time for success in your drug discovery journey.

This email address is being protected from spambots. You need JavaScript enabled to view it.

STREAM OUR WEBINAR

Meet with Dr. Holfack to discuss the terms of a possible collaboration to further develop together our Kinase inhibitor development products based on Nanocyclix® technology.

This email address is being protected from spambots. You need JavaScript enabled to view it.

[Congress] European Association of Nuclear Medicine Annual Meeting, October 22 – 30 – EANM 2020

 [Congress] European Association of Nuclear Medicine Annual Meeting , October 22 – 30 EANM 2020

Cyril Berthet is attending the European Association of Nuclear Medicine Annual Meeting.

The EANM Annual Congress is the most valuable Nuclear Medicine Meeting worldwide. This is the place to be to engage conversation about the latest and newest trends and outcome in Nuclear Medicine.

It takes 2 to tango: compound labeling and complementary imaging approaches to show how your compound works & targets the right patient.

Through pharmaco-imaging, the results of preclinical studies can influence the early decision to continue or interrupt the development of a drug candidate.
In the clinical development phase, imaging offers an exceptional opportunity to follow the drug in humans with the same techniques developed during the preclinical phase.
Novel therapies are converging towards precision medicine, for which pharmaco-imaging is indispensable to all players in the drug development cycle – from the pharmaceutical industry to clinicians – to ensure that the most appropriate treatments are being matched to the needs of the patient.

Explore our multi-modal pharmaco-imaging & targeted radiotherapy expertise for your preclinical projects:

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational nuclear medicine biomarkers
  • Evaluation of targeted radiotherapy efficacy

Schedule a meeting with Cyril!

[Congress] Bio Japan, October 14-16, 2020

[Congress] Bio Japan, October 14-16, 2020

It has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades.
It focuses on the new researchers who have come up with innovations which would help in the future of mankind.

Choose innovation, choose Oncodesign.
We create an integrated drug discovery & development solution to help you from the early phases up to IND (Investigational New Drug)

An integrated drug discovery & development solution from hit finding to IND filing in less than 3 years

DRIVE™ is a smart and agile solution to help clients streamline their drug discovery and development programs and to make best use of their resources and achieve optimum results.
DRIVE™ offers a complete drug discovery and development solution through the whole value chain from hit finding to IND filing, aiming to accelerate the entry of the client new chemical entities into clinic within a 3 to 4 years timeframe to deliver an IND.

DRIVE™ premium solution timeline

Our expert Emily Fang will participate to give you the answers you need to make the right decisions at the right time for success in your drug discovery journey.

This email address is being protected from spambots. You need JavaScript enabled to view it.

STREAM OUR WEBINAR

Dr. Hoflack will be introducing our Nanocyclix® products pipeline to open up a path to new kinases of therapeutic interest. He is thrilled to discuss any partnership opportunities to welcome on you onboard.

This email address is being protected from spambots. You need JavaScript enabled to view it.